Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum

Area of Science:

• Cardiovascular Medicine
• Genetics
• Epidemiology

Background:

• Elevated lipoprotein(a) (Lp[a]) is increasingly recognized as a significant risk factor for coronary heart disease (CHD).
• Genetic and epidemiological studies strongly support a causal link between Lp[a] and CHD development.
• Despite growing interest, fundamental questions regarding Lp[a]'s role persist.

Purpose of the Study:

• To review the current understanding of lipoprotein(a) (Lp[a]) as a risk factor for coronary heart disease (CHD).
• To highlight the unresolved questions surrounding Lp[a]'s pathogenic mechanisms and clinical utility.
• To discuss the current therapeutic landscape for lowering Lp(a) levels.

Main Methods:

• Review of recent genetic and epidemiological data.
• Analysis of current clinical understanding and unanswered questions.
• Examination of existing and emerging therapeutic interventions.

Main Results:

• Strong evidence supports a causal role for Lp[a] in CHD.
• The precise pathogenic mechanisms of Lp[a] remain largely unknown.
• Uncertainty exists regarding the optimal clinical application of Lp(a) measurements.
• No specific therapies currently exist to lower Lp[a] concentrations, though some agents also reduce LDL.

Conclusions:

• Lipoprotein(a) is a confirmed causal risk factor for coronary heart disease.
• Further research is needed to elucidate Lp[a]'s pathogenic pathways and establish clear clinical guidelines.
• Development of targeted therapies to specifically reduce Lp[a] is an unmet clinical need.